Gujarat Kidney & Super Speciality share price today

Gujarat Kidney & Super Speciality Ltd's share price was ₹159.71 at the close on 4 November 2026. It has been rising for 37 weeks. That is 12.5% above its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Gujarat Kidney & Super Speciality Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 2 January 2026, it has traded between ₹99 and ₹195, and at that close it sat 63% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 10 months the share price moved +55% while the NIFTY 500 moved −9%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1 points on a year earlier, revenue up on a year earlier for 4 quarters in a row (every quarter we can compare) and highest quarterly revenue in 8 quarters.

1. Operating margin down 32.1 points on a year earlier

   24.4% in the June 2026 quarter, from 56.5%.

2. Revenue up on a year earlier for 4 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹34 crore, +124.7% on a year earlier.

3. Highest quarterly revenue in 8 quarters

   Revenue of ₹34 crore in the June 2026 quarter is the highest of the last 8 quarters.

For April to June 2026 (the quarter ended 30 June 2026), Gujarat Kidney & Super Speciality reported revenue of ₹34.3 crore, up 124.7% from ₹15.3 crore a year earlier, and a profit of ₹5.32 crore, down 1.5% from ₹5.40 crore.

Gujarat Kidney & Super Speciality results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Gujarat Kidney & Super Speciality closed at ₹159.71 on 4 November 2026. Its highest weekly close since January 2026 was ₹194.27 on 1 October 2026.

Gujarat Kidney & Super Speciality share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

52 weekly closes from 2 January 2026 to 4 November 2026.

4 Nov 2026: Gujarat Kidney & Super Speciality closed at ₹159.71, down 2.2% on the week and down 17.8% on the month. Results for April to June 2026: Revenue up 124.7% and profit down 1.5% on a year earlier.

Gujarat Kidney & Super Speciality has paid no dividend on the NSE since its first NSE close in our records (2 January 2026), the start of the period we checked.

No. Gujarat Kidney & Super Speciality Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Gujarat Kidney & Super Speciality's management made 0 promises we could check against what it later reported.

Our read after the latest results, written 31 May 2026.

₹6.61 lakh + ₹20,000 exchange fines and a financial restatement within 6 months of listing, compliance infrastructure lagging growth pace.

The main risks

• Governance and compliance immaturity: ₹6.61 lakh + ₹20,000 exchange fines and a financial restatement within 6 months of listing, compliance infrastructure lagging growth pace. ✓ fact
• Operating margin compression may persist: Operating margin 20.6% (January to March 2026) vs 56% peak, depends on bed utilization ramp at four newly acquired hospitals. ✓ fact
• Geographic concentration, single-state risk: All revenue from Gujarat, regulatory or competitive disruption at state level is an outsized risk for current scale. ✓ fact

Our read after the latest results, written 31 May 2026.

Gujarat Kidney & Super Speciality is not on any of our India lists this week.

Gujarat Kidney & Super Speciality Ltd earned ₹5.3 Cr of net profit in the Jun 2026 quarter, −1.5% on the same quarter a year earlier. Full-year FY26 profit was ₹17.0 Cr. That is 15.5% of the quarter's revenue. The same quarter a year earlier earned ₹5.4 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹17.0 Cr (+70.0% on the year before).

Why profit moved: revenue changed +124.7% on a year earlier and the margin moved −32.1 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +75.4% and revenue +118.0%. Profit is growing slower than sales: rising costs are taking part of the growth.

Gujarat Kidney & Super Speciality Ltd reported ₹34.3 Cr of revenue in the Jun 2026 quarter, +124.7% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. The last full year, FY26, came in at ₹82.0 Cr. The last four reported quarters add to ₹101 Cr.

Revenue is everything the company billed its customers in the period.

A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

FY26 revenue was ₹82.0 Cr, +105.0% on the year before.

Gujarat Kidney & Super Speciality Ltd's operating margin was 24.4% in the Jun 2026 quarter, 32.1 percentage points lower than the same quarter a year ago. Across 3 years it has been between 33.0% and 41.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. OPM fell from 56.49% (Q1 FY26, per) to 20.60% (Q4 FY26, per) as acquired hospitals with higher cost structures were consolidated. Expenses grew from ₹6.64 Cr to ₹24.28 Cr in the same period (per). If bed utilization at Parekhs and Patel Hospital ramps, fixed cost leverage should restore margins toward the 30-35% band.

Why the margin moved: operating margin changed −32.1 percentage points on the year while gross margin changed −3.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 38% of Gujarat Kidney & Super Speciality Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹4.0 Cr of cash, against ₹17.0 Cr of profit. After ₹103 Cr of spending on assets, free cash was −₹107 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 38% of profit came in as cash: the cash cycle got 149 days shorter between FY24 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: the bigger use of cash is spending on new assets, at 17.1× depreciation over three years. The next section checks what that spending is building.

Gujarat Kidney & Super Speciality Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 172 days in FY26, down from 321 days in FY24. It spent ₹137 Cr on assets over the last 3 years. Customers take 172 days to pay, and stock sits for 82 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹82.0 Cr, each day of that cycle ties up about ₹0.2 Cr, so roughly ₹39.0 Cr is tied up in the business at any time.

FY26: customers took 172 days to pay and stock sat for 82 days, about 2.7 months of sales sitting as stock, for a full cycle of 172 days, shorter than FY24's 321.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 82 days. Customers pay about 172 days after that. Suppliers are paid at 339 days. Together that makes the 172-day cycle.

Spending on assets: ₹137 Cr over the last 3 years, against ₹8.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Gujarat Kidney & Super Speciality Ltd's P/E is 79.7×, in the middle of its own history: higher than 54% of past readings. Its usual P/E (the middle reading) is 76.4×, over 10 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹2.14.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Gujarat Kidney & Super Speciality Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Gujarat Kidney & Super Speciality Ltd's story is not scored yet against the checks our research set on 31 May 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Four acquisitions, no prior integration experience at Parekhs' scale, margin recovery timeline may slip.

NOT YET CHECKED

What is not proven yet. Four acquisitions, no prior integration experience at Parekhs' scale, margin recovery timeline may slip.

The test written in advance. Two consecutive post-Parekhs quarters showing OPM recovering back above 30% with debtor days falling below 120 - i.e. evidence the acquired beds are delivering real operating leverage rather than just diluting margins. Measured by: the thesis as written as stated.

Sources: our stock research file (31 May 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes.

Gujarat Kidney & Super Speciality Ltd earned a ROCE of 14% in FY26. Its return on capital used (ROIC) is 3.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 20.7% net margin and 0.28× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 20.7% net margin × 0.28× asset turnover × 1.18× leverage (assets divided by equity) ≈ 6.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 8.2% − 12.0% = −3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 8.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Gujarat Kidney & Super Speciality Ltd has total debt of ₹29.0 Cr against shareholder equity of ₹255 Cr as of Jun 2026, so its debt is 0.11× its equity, which is very little. Year by year, that ratio went from 0.30 in FY25 to 0.11 in FY26.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

So the returns on this page come from the business, not from borrowed money.

No group of Gujarat Kidney & Super Speciality Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For Gujarat Kidney & Super Speciality Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

48.2 out of 100, rank 3 of 7 in Hospitals/Medical Services, with 63% of the evidence available.

Gujarat Kidney & Super Speciality Ltd scores 48.2 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 3. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.

The three scored parts add up to the total exactly: 23.9 + 13 + 11.3 = 48.2 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Gujarat Kidney & Super Speciality ranks 3 of 7 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 48.2 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals/Medical Services, all 7 compared on one page.

Gujarat Kidney & Super Speciality is the 4th largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Agarwals Health Care, Park Medi World and Nephrocare Health Services. Just below it: Unihealth Hospitals, Gaudium IVF and Women Health and KRM Ayurveda.

Hospitals/Medical Services companies close in size

1. Dr Agarwals Health Care Ltd ₹16,144 crore
2. Park Medi World Ltd ₹9,490 crore
3. Nephrocare Health Services Ltd ₹6,180 crore
4. Gujarat Kidney & Super Speciality Ltd ₹1,288 crore
5. Unihealth Hospitals Ltd ₹875 crore
6. Gaudium IVF and Women Health Ltd ₹771 crore
7. KRM Ayurveda Ltd ₹479 crore

All 7 Hospitals/Medical Services companies, largest first

Companies close in size in other industries

1454. India Pesticides Ltd ₹1,297 crore · Pesticides/Agrochemicals
1455. Sanghi Industries Ltd ₹1,289 crore · Cement Products
1456. Gujarat Kidney & Super Speciality Ltd ₹1,288 crore
1457. All Time Plastics Ltd ₹1,286 crore · Plastics - Others
1458. Chamanlal Setia Exports Ltd ₹1,285 crore · FMCG - Rice

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.